Department of Vascular and Oncological Interventional Radiology, AP-HP, centre, Hôpital Européen Georges-Pompidou, 75015 Paris, France; Université de Paris, 75006 Paris, France.
Department of Vascular and Oncological Interventional Radiology, AP-HP, centre, Hôpital Européen Georges-Pompidou, 75015 Paris, France; Université de Paris, 75006 Paris, France.
Diagn Interv Imaging. 2021 Mar;102(3):141-145. doi: 10.1016/j.diii.2020.12.003. Epub 2021 Jan 7.
To evaluate the influence of intravesical prostatic protrusion (IPP) on clinical outcomes after prostatic artery embolization (PAE) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
All consecutive patients who underwent PAE for lower urinary tract symptoms between January 2017 and January 2019 were retrospectively included. IPP was evaluated on pre-treatment magnetic resonance imaging examination and symptoms were assessed at follow-up consultations using the international prostate symptom score (IPSS) and quality of life (QOL) questionnaire. IPPs were classified as grade 1 (<5mm), grade 2 (5-10mm), or grade 3 (>10mm).
A total of 160 consecutive men (mean age 65±7.8 [SD] years; range: 45-89 years), underwent PAE. The mean IPSS was 21±7.3 (SD) (range: 5-35) and prostate volume 87±38 (SD) mL (range: 30-200mL). The IPP grade was 1 for 28 (28/160; 18%), 2 for 52 (52/160; 33%), and 3 for 80 (80/160; 50%) patients. There were no significant differences in IPSS at baseline between the three IPP grades. Patients with severe (grade 3) IPP had a significantly higher reduction in IPSS than those with non-severe IPP (grade 1 or 2), with estimated mean reductions of 12±2.5 (SD) (range: -4-28) and 8.3±1.9 (SD) (range: -8-21) (P=0.02), respectively. The mean reduction in the QOL score was 3.0 for grade 3 and 2.0 for grade 1 or 2 IPP (P=0.02).
The degree of IPP does not limit the efficacy of PAE in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
评估前列腺内突（IPP）对前列腺动脉栓塞（PAE）治疗良性前列腺增生症患者下尿路症状的临床疗效的影响。
回顾性纳入 2017 年 1 月至 2019 年 1 月期间因下尿路症状接受 PAE 的所有连续患者。IPP 于治疗前磁共振成像检查中评估，并通过国际前列腺症状评分（IPSS）和生活质量（QOL）问卷在随访时评估症状。IPP 分为 1 级（<5mm）、2 级（5-10mm）或 3 级（>10mm）。
共纳入 160 例连续男性患者（平均年龄 65±7.8[SD]岁；范围：45-89 岁），行 PAE 治疗。平均 IPSS 为 21±7.3（SD）（范围：5-35），前列腺体积 87±38（SD）mL（范围：30-200mL）。IPP 分级 1 级 28 例（28/160；18%），2 级 52 例（52/160；33%），3 级 80 例（80/160；50%）。三组 IPP 患者的基线 IPSS 无显著差异。IPP 严重（3 级）患者的 IPSS 降低程度明显大于非严重（1 级或 2 级）患者，估计平均降低 12±2.5（SD）（范围：-4-28）和 8.3±1.9（SD）（范围：-8-21）（P=0.02）。3 级 IPP 的 QOL 评分平均降低 3.0，1 级或 2 级 IPP 降低 2.0（P=0.02）。
IPP 程度并不限制 PAE 治疗良性前列腺增生症患者下尿路症状的疗效。
